Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1970 Aug;49(8):1578–1588. doi: 10.1172/JCI106375

Factor V anticoagulants: clinical, biochemical, and immunological observations

Donald I Feinstein 1, Samuel I Rapaport 1, William G McGehee 1, Mary Jane Patch 1
PMCID: PMC322637  PMID: 4194089

Abstract

A patient who had received multiple transfusions for complications of acute hemorrhagic pancreatitis developed a potent factor V anticoagulant with bleeding due to defective hemostasis. Despite its potency, the anticoagulant disappeared within 15 days of its first manifestation. A second patient with adenocarcinoma of the colon developed an anticoagulant to factor V postoperatively after a single blood transfusion. The anticoagulants appeared to react stoichiometrically with factor V in normal plasma in vitro. They had the physicochemical properties of immunoglobulins, and their activity was neutralized by antihuman immunoglobulin antiserum. One anticoagulant appeared to be slightly more active against homologous than against autologous factor V, but it also inhibited heterologous factor V. Both anticoagulants progressively inactivated intrinsic prothrombin activator formed from normal reagents in the incubation mixture of the thromboplastin generation test, thus confirming that factor V is required for the effective action of the intrinsic prothrombin activator. Since the anticoagulants were immunoglobulins whose activity was consumed in their reaction with factor V, consumption of anticoagulant activity was used to detect factor V antigenic material in test materials. Human serum without factor V clotting activity was found to consume anticoagulant activity, i.e., to contain inactive factor V antigenic material. Plasma from two patients with hereditary factor V deficiency (parahemophilia) failed to consume significant anticoagulant activity. Thus, the lack of factor V activity in these patients represents a deficiency of factor V molecules rather than the synthesis of a defective molecule with impaired clotting activity.

Full text

PDF
1578

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cole E. R., Koppel J. L., Olwin J. H. Phospholipid-protein interactions in the formation of prothrombin activator. Thromb Diath Haemorrh. 1965 Nov 15;14(3-4):431–444. [PubMed] [Google Scholar]
  2. Denson K. W. 2 forms of haemophilia? Lancet. 1968 Jul 27;2(7561):222–223. doi: 10.1016/s0140-6736(68)92661-5. [DOI] [PubMed] [Google Scholar]
  3. FAHEY J. L., HORBETT A. P. Human gamma globulin fractionation on anion exchange cellulose columns. J Biol Chem. 1959 Oct;234:2645–2651. [PubMed] [Google Scholar]
  4. FERGUSON J. H., JOHNSTON C. L., Jr, HOWELL D. A. A circulation inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood. 1958 Apr;13(4):382–397. [PubMed] [Google Scholar]
  5. FRANKLIN E. C. Structural units of human 7S gamma globulin. J Clin Invest. 1960 Dec;39:1933–1941. doi: 10.1172/JCI104218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feinstein D. I., Rapaport S. I., Chong M. N. Immunologic characterization of 12 factor VIII inhibitors. Blood. 1969 Jul;34(1):85–90. [PubMed] [Google Scholar]
  7. Feinstein D., Chong M. N., Kasper C. K., Rapaport S. I. Hemophilia A: polymorphism detectable by a factor 8 antibody. Science. 1969 Mar 7;163(3871):1071–1072. doi: 10.1126/science.163.3871.1071. [DOI] [PubMed] [Google Scholar]
  8. HJORT P., RAPAPORT S. I., OWREN P. A. A simple, specific one-stage prothrombin assay using Russell's viper venom in cephalin suspension. J Lab Clin Med. 1955 Jul;46(1):89–97. [PubMed] [Google Scholar]
  9. HJORT P., RAPAPORT S. I., OWREN P. A. Evidence that platelet accelerator (platelet factor 1) is adsorbed plasma proaccelerin. Blood. 1955 Nov;10(11):1139–1150. [PubMed] [Google Scholar]
  10. HOUGIE C. A simple assay method for factor X (Stuart-Prower factor). Proc Soc Exp Biol Med. 1962 Mar;109:754–756. doi: 10.3181/00379727-109-27328. [DOI] [PubMed] [Google Scholar]
  11. Handley D. A., Duncan B. M. A circulating anticoagulant specific for factor V. Pathology. 1969 Oct;1(4):265–272. doi: 10.3109/00313026909071305. [DOI] [PubMed] [Google Scholar]
  12. Hougie C., Twomey J. J. Haemophilia Bm: a new type of factor-IX deficiency. Lancet. 1967 Apr 1;1(7492):698–700. doi: 10.1016/s0140-6736(67)92179-4. [DOI] [PubMed] [Google Scholar]
  13. Hoyer L. W., Breckenridge R. T. Immunologic studies of antihemophilic factor (AHF, factor VIII): cross-reacting material in a genetic variant of hemophilia A. Blood. 1968 Dec;32(6):962–971. [PubMed] [Google Scholar]
  14. Jobin F., Esnouf M. P. Studies on the formation of the prothrombin-converting complex. Biochem J. 1967 Mar;102(3):666–674. doi: 10.1042/bj1020666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. KUNKEL H. G. Zone electrophoresis. Methods Biochem Anal. 1954;1:141–170. doi: 10.1002/9780470110171.ch6. [DOI] [PubMed] [Google Scholar]
  16. Lopez V., Pflugshaupt R., Bütler R. A specific inhibitor of human clotting factor V. Acta Haematol. 1968;40(5):275–285. doi: 10.1159/000208915. [DOI] [PubMed] [Google Scholar]
  17. Morrison F. S., Mollison P. L. Post-transfusion purpura. N Engl J Med. 1966 Aug 4;275(5):243–248. doi: 10.1056/NEJM196608042750503. [DOI] [PubMed] [Google Scholar]
  18. PAPAHADJOPOULOS D., HANAHAN D. J. OBSERVATIONS ON THE INTERACTION OF PHOSPHOLIPIDS AND CERTAIN CLOTTING FACTORS IN PROTHROMBIN ACTIVATOR FORMATION. Biochim Biophys Acta. 1964 Aug 19;90:436–439. doi: 10.1016/0304-4165(64)90220-x. [DOI] [PubMed] [Google Scholar]
  19. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  20. RAPAPORT S. I., AMES S. B. Clotting factor assays on plasma from patients receiving intramuscular of subcutaneous heparin. Am J Med Sci. 1957 Dec;234(6):678–686. doi: 10.1097/00000441-195712000-00006. [DOI] [PubMed] [Google Scholar]
  21. RAPAPORT S. I., AMES S. B., DUVALL B. J. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood. 1960 Feb;15:212–227. [PubMed] [Google Scholar]
  22. RAPAPORT S. I., SCHIFFMAN S., PATCH M. J., AMES S. B. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood. 1963 Feb;21:221–236. [PubMed] [Google Scholar]
  23. RAPAPORT S. I., SCHIFFMAN S., PATCH M. J., WARE A. G. A simple, specific one-stage assay for plasma thromboplastin antecedent activity. J Lab Clin Med. 1961 May;57:771–780. [PubMed] [Google Scholar]
  24. Rapaport S. I., Hjort P. F., Patch M. J., Jeremic M. Consumption of serum factors and prothrombin during intravascular clotting in rabbits. Scand J Haematol. 1966;3(1):59–75. doi: 10.1111/j.1600-0609.1966.tb00626.x. [DOI] [PubMed] [Google Scholar]
  25. Rapaport S. I., Hjort P. F., Patch M. J. Rabbit factor V: different effects of thrombin and venom, a source of error in assay. Am J Physiol. 1966 Dec;211(6):1477–1485. doi: 10.1152/ajplegacy.1966.211.6.1477. [DOI] [PubMed] [Google Scholar]
  26. Roberts H. R., Grizzle J. E., McLester W. D., Penick G. D. Genetic variants of hemophilia B: detection by means of a specific PTC inhibitor. J Clin Invest. 1968 Feb;47(2):360–365. doi: 10.1172/JCI105732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. SCHIFFMAN S., RAPAPORT S. I., PATCH M. J. STARCH BLOCK ELECTROPHORESIS OF PLASMA AND SERUM CLOTTING FACTORS. SEPARATION OF ACTIVATED PTC (PTC). Blood. 1965 May;25:724–735. [PubMed] [Google Scholar]
  28. SCHIFFMAN S., RAPAPORT S. I., PATCH M. J. THE IDENTIFICATION AND SYNTHESIS OF ACTIVATED PLASMA THROMBOPLASTIN COMPONENT (PTC'). Blood. 1963 Dec;22:733–749. [PubMed] [Google Scholar]
  29. STORMORKEN H. The preparation of proaccelerin deficient (parahemophilia) plasma for the assay of proaccelerin. Scand J Clin Lab Invest. 1957;9(3):273–276. doi: 10.3109/00365515709079970. [DOI] [PubMed] [Google Scholar]
  30. Shapiro S. S., Carroll K. S. Acquired factor 8 antibodies: further immunologic and electrophoretic studies. Science. 1968 May 17;160(3829):786–787. doi: 10.1126/science.160.3829.786. [DOI] [PubMed] [Google Scholar]
  31. Shapiro S. S. The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8. J Clin Invest. 1967 Feb;46(2):147–156. doi: 10.1172/JCI105517. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES